Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2242f4fad0f14c2

Jump to content

Monalizumab

Edit links
From Wikipedia, the free encyclopedia
(Redirected from IPH2201)
Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Mechanism of action

[edit]

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]

References

[edit]
  1. ↑ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. ↑ IPH2201 studies
  3. ↑ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. ↑ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. ↑ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
  6. ↑ van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1) 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Monalizumab&oldid=1334063597"